Registrational Phase III CLARIFY trial: Target number of participants achieved

Clarity completes Phase III trial enrollment for prostate cancer diagnostic; topline data due 2027.

What the company is saying

Clarity Pharmaceuticals announces it has dosed the planned 383 participants in its registrational Phase III CLARIFY trial for 64Cu-SAR-bisPSMA, a diagnostic agent for high-risk prostate cancer. The announcement emphasizes this as a pivotal milestone, positioning the company for a future US FDA submission. The company highlights prior Phase I data showing 30% greater lesion detection and higher tracer uptake versus standard agents, and stresses the unmet need due to current PSMA PET agents' sensitivities of only 27%-40%. Dr Alan Taylor, Executive Chairperson, frames the trial as a potential paradigm shift for prostate cancer management, citing both improved diagnostic performance and broader accessibility. The tone is confident and forward-looking, with repeated references to addressing a significant clinical gap and the potential for regulatory approval. The company also discloses that both CLARIFY and AMPLIFY Phase III trials have completed recruitment and are in patient follow-up.

What the data suggests

The company has met its Phase III CLARIFY trial enrollment goal of 383 participants, a key operational milestone. Prior Phase I PROPELLER data showed approximately 30% greater lesion detection with 64Cu-SAR-bisPSMA PET compared to 68Ga-PSMA-11 PET, and a higher proportion of participants with more lesions identified (73% vs. 27%). Currently approved PSMA PET agents have reported sensitivities of 27%-40% in detecting pelvic lymph node metastases, with none meeting prespecified sensitivity thresholds in pivotal trials. The announcement references the large US prostate cancer burden, with 333,830 new cases and 36,320 deaths projected for 2026. No financial metrics, revenue, or cost figures are disclosed. The topline data from CLARIFY and AMPLIFY are expected in the first half of 2027, and the products remain unregistered with safety and efficacy not yet assessed by the FDA or TGA.

Analysis

The announcement is generally positive in tone, highlighting the completion of enrollment for the pivotal Phase III CLARIFY trial and referencing promising Phase I results. The key realised milestone is the dosing of 383 participants, which is a concrete operational achievement. However, the majority of the anticipated benefits—regulatory submission, product approval, and commercial impact—are forward-looking and contingent on topline data expected in the first half of 2027, nearly two years away. The language includes aspirational statements about paradigm shifts and improved patient outcomes, but these are not yet substantiated by Phase III data. There is no disclosure of financial metrics, revenue, or profitability, and while the trial is capital-intensive by nature, no new capital outlay or spend is disclosed in this update. The gap between narrative and evidence is moderate: the company has achieved a significant clinical milestone, but the ultimate value proposition remains unproven until trial results and regulatory outcomes are known.

Risk flags

• ●The main execution risk is that topline data for the CLARIFY trial will not be available until the first half of 2027, leaving a long period with no new efficacy or safety information. This delay exposes the company to market and operational uncertainties.
• ●Regulatory approval is contingent on the trial meeting its primary endpoints for sensitivity and specificity, but no Phase III efficacy or safety data have been disclosed. Failure to achieve these endpoints would undermine the product's commercial prospects.
• ●Both 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA are unregistered products whose safety and efficacy have not been assessed by regulators, so there is no guarantee of eventual approval or market access.
• ●The company provides no financial data or guidance in this announcement, making it impossible to assess current cash runway, funding needs, or the financial risk of continued development.
• ●The competitive landscape includes existing PSMA PET agents, and while Clarity claims superior performance, these assertions are based on early-phase or cross-trial comparisons rather than head-to-head pivotal data.

Bottom line

Clarity Pharmaceuticals has achieved full enrollment in its pivotal Phase III CLARIFY trial for a novel prostate cancer diagnostic, marking a significant operational step. The company presents strong early-phase data suggesting improved lesion detection over current standards, but no Phase III results are yet available. All commercial and regulatory benefits depend on topline data expected in the first half of 2027, so investors face a long wait for meaningful catalysts. The absence of financial disclosures leaves open questions about funding and development risk. The most important takeaway is that while the company is on track operationally, the investment case hinges entirely on future trial results and subsequent regulatory review.

Announcement summary

(ASX:CU6) Clarity Pharmaceuticals announced that its registrational Phase III CLARIFY trial (NCT06056830) has dosed the planned target of 383 participants. The CLARIFY trial is the first Phase III registrational trial for Clarity and is being conducted in the United States and Australia. The study is a non-randomised, open-label trial of 64Cu-SAR-bisPSMA in participants with untreated, histopathology-confirmed prostate cancer with high-risk features who are proceeding to radical prostatectomy with pelvic lymph node dissection. The primary endpoints are the sensitivity and specificity of 64Cu-SAR-bisPSMA to detect prostate cancer within the pelvic lymph nodes compared to histopathology, assessed independently for Day 1 (1-4 hours post-administration) and Day 2 (approximately 24 hours post-administration). The CLARIFY trial builds on the Phase I PROPELLER study, which involved 30 participants and demonstrated approximately 30% greater lesion detection with 64Cu-SAR-bisPSMA PET compared to 68Ga-PSMA-11 PET, 2-3 times higher tracer uptake and contrast, and a higher proportion of participants with more lesions identified by 64Cu-SAR-bisPSMA (73% vs. 27%). The improved diagnostic performance of next-day versus same-day 64Cu-SAR-bisPSMA PET was also observed in the COBRA and Co-PSMA trials in biochemical recurrence. Topline data from the CLARIFY trial are anticipated in the first half of calendar year 2027, along with topline results from the AMPLIFY trial, which is investigating 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer. The final CLARIFY study results are intended to provide sufficient evidence to support an application to the US Food and Drug Administration (FDA) for approval of 64Cu-SAR-bisPSMA as a new diagnostic imaging agent in prostate cancer patients prior to definitive therapy. Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, stated that the company now has two registrational Phase III trials with 64Cu-SAR-bisPSMA that have completed recruitment and are in patient follow-up. Currently approved PSMA PET agents have reported sensitivities of 27%-40% in their respective Phase III pivotal studies for detection of pelvic lymph node metastases prior to prostatectomy, and none achieved the prespecified primary endpoint thresholds for sensitivity. The American Cancer Institute estimates there will be about 333,830 new cases of prostate cancer in the US in 2026 and around 36,320 deaths from the disease. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with copper-64 for imaging and copper-67 for therapy. 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA are unregistered products and their safety and efficacy have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA).

Disagree with this article?